



IFW

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450
Alexandria, VA 22313 on November 8, 2004.

INFORMATION DISCLOSURE
STATEMENT

Examining Group 1614
Patent Application
Docket No. USF-T194XC1
Serial No. 10/784,309


Doran R. Pace, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Stephen Jae Lee
Art Unit : 1614
Applicants : James Turkson, Richard Jove, Said Sebti, Andrew D. Hamilton
Serial No. : 10/784,309
Filed : February 20, 2004
Conf. No. : 2143
For : Peptidomimetic Inhibitors of STAT Activity and Uses Thereof

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed. However, Applicants have not submitted a copy of the U.S. patent cited on attached Form PTO/SB/08 pursuant to the Notice at 1276 OG 55 waiving the requirement set forth at 37 CFR 1.98(a)(2)(i).

The reference by Posternak *et al.* (1945), cited as R50 on the attached PTO/SB/08B, is written in a foreign language. In accordance with MPEP §609A(3), Applicants are submitting herewith a copy of the International Search Report from corresponding International Application No. PCT/US2004/005030 which was filed on February 20, 2004; the International Search Report cites the Posternak *et al.* (1945) reference therein.

It is respectfully requested that the references cited on the attached form PTO/SB/08 be considered in the examination of the subject application and that their consideration be made of record.

Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



Doran R. Pace
Patent Attorney
Registration No. 38,261
Phone No.: 352-375-8100
Fax No.: 352-372-5800
Address: P.O. Box 142950
Gainesville, FL 32614-2950

DRP/sl

Attachments: Form PTO/SB/08; copies of references cited therein; copy of International Search Report.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/784,309	
			Filing Date	February 20, 2004	
			First Named Inventor	James Turkson	
			Group Art Unit	1614	
Examiner Name					
Sheet	2	of	6	Attorney Docket Number	USF-T194XC1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	AKIRA, S. "Roles of STAT3 defined by tissue-specific gene targeting" <i>Oncogene</i> , 2000, pp. 2607-2611, Vol. 19.	
	R2	BECKER, S. <i>et al.</i> "Three-dimensional structure of the Stat3 β homodimer bound to DNA" <i>Nature</i> , July 9, 1998, pp. 145-151, Vol. 394.	
	R3	BERG, T. <i>et al.</i> "Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts" <i>PNAS</i> , March 19, 2002, pp. 3830-3835, Vol. 99, No. 6.	
	R4	BOWMAN, T. <i>et al.</i> "STATs in oncogenesis" <i>Oncogene</i> , 2000, pp. 2474-2488, Vol. 19.	
	R5	BOWMAN, T. <i>et al.</i> "Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis" <i>PNAS</i> , June 19, 2001, pp. 7319-7324, Vol. 98, No. 13.	
	R6	BROMBERG, J. <i>et al.</i> "Stat3 Activation Is Required for Cellular Transformation by v-src" <i>Molecular and Cellular Biology</i> , May 1998, pp. 2553-2558, Vol. 18, No. 5.	
	R7	BROMBERG, J. <i>et al.</i> "The role of STATs in transcriptional control and their impact on cellular function" <i>Oncogene</i> , 2000, pp. 2468-2473, Vol. 19.	
	R8	BUETTNER, R. <i>et al.</i> "Activated STAT Signaling in Human Tumors Provides Novel Molecular Targets for Therapeutic Intervention" <i>Clinical Cancer Research</i> , April 2002, pp. 945-954, Vol. 8.	
	R9	CATLETT-FALCONE, R. <i>et al.</i> "STAT proteins as novel targets for cancer therapy" <i>Current Opinion in Oncology</i> , 1999, pp. 490-496, Vol. 11.	
	R10	CATLETT-FALCONE, R. <i>et al.</i> "Constitutive Activation of Stat3 Signaling Confers Resistance to Apoptosis in Human U266 Myeloma Cells" <i>Immunity</i> , January 1999, pp. 105-115, Vol. 10.	
	R11	CHEN, X. <i>et al.</i> "Crystal Structure of a Tyrosine Phosphorylated STAT-1 Dimer Bound to DNA" <i>Cell</i> , May 29, 1998, pp. 827-839, Vol. 93.	
	R12	DARNELL, J. E., Jr. "STATs and Gene Regulation" <i>Science</i> , September 12, 1997, pp. 1630-1635, Vol. 277.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/784,309
				Filing Date	February 20, 2004
				First Named Inventor	James Turkson
				Group Art Unit	1614
				Examiner Name	
Sheet	3	of	6	Attorney Docket Number	USF-T194XC1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R13	DARNELL, J. E., Jr. "Transcription Factors As Targets For Cancer Therapy" <i>Nat. Rev. Cancer</i> , October 2002, pp. 740-749, Vol. 2.	
	R14	EPLING-BURNETTE, P. K. <i>et al.</i> "Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression" <i>The Journal of Clinical Investigation</i> , February 2001, pp. 351-361, Vol. 107, No. 3.	
	R15	FRANK, D. A. "STAT Signaling in the Pathogenesis and Treatment of Cancer" <i>Molecular Medicine</i> , 1999, pp. 432-456, Vol. 5.	
	R16	GARCIA, R. <i>et al.</i> "Constitutive Activation of Stat3 in Fibroblasts Transformed by Diverse Oncoproteins and in Breast Carcinoma Cells" <i>Cell Growth & Differentiation</i> , December 1997, pp. 1267-1276, Vol. 8.	
	R17	GARCIA, R. <i>et al.</i> "Activation of STAT Transcription Factors in Oncogenic Tyrosine Kinase Signaling" <i>Journal of Biomedical Science</i> , 1998, pp. 79-85, Vol. 5.	
	R18	GARCIA, R. <i>et al.</i> "Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells" <i>Oncogene</i> , 2001, pp. 2499-2513, Vol. 20.	
	R19	GIBSON, B. W. <i>et al.</i> "Liquid Secondary Ionization Mass Spectrometric Characterization of Two Synthetic Phosphotyrosine-Containing Peptides" <i>J. Am. Chem. Soc.</i> , 1987, pp. 5343-5348, Vol. 109.	
	R20	GOUILLEUX, F. <i>et al.</i> "Prolactin and Interleukin-2 Receptors in T Lymphocytes Signal through a MGF-STAT5-Like Transcription Factor" <i>Endocrinology</i> , 1995, pp. 5700-5708, Vol. 136, No. 12.	
	R21	GRANDIS, J. R. <i>et al.</i> "Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis <i>in vivo</i> " <i>PNAS</i> , April 11, 2000, pp. 4227-4232, Vol. 97, No. 8.	
	R22	HIRANO, T. <i>et al.</i> "Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors" <i>Oncogene</i> , 2000, pp. 2548-2556, Vol. 19.	
	R23	HORVATH, C. M. "STAT proteins and transcriptional responses to extracellular signals" <i>TIBS</i> , October 2000, pp. 496-502, Vol. 25.	
	R24	JOHNSON, P. J. <i>et al.</i> "Overexpressed pp60 ^{c-src} Can Induce Focus Formation Without Complete Transformation of NIH 3T3 Cells" <i>Molecular and Cellular Biology</i> , May 1985, pp. 1073-1083, Vol. 5, No. 5.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/784,309
				Filing Date	February 20, 2004
				First Named Inventor	James Turkson
				Group Art Unit	1614
				Examiner Name	
Sheet	4	of	6	Attorney Docket Number	USF-T194XC1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R25	JONES, G. <i>et al.</i> "Development and Validation of a Genetic Algorithm for Flexible Docking" <i>J. Mol. Biol.</i> , 1997, pp. 727-748, Vol. 267.	
	R26	KITAS, E. A. <i>et al.</i> "Synthesis of O-Phosphotyrosine-Containing Peptides. 3. Synthesis of H-Pro-Try(P)-Val-OH via Dimethyl Phosphate Protection and the Use of Improved Deprotection Procedures" <i>J. Org. Chem.</i> , 1990, pp. 4181-4187, Vol. 55.	
	R27	KOTENKO, S. V. <i>et al.</i> "Jak-Stat signal transduction pathway through the eyes of cytokine class II receptor complexes" <i>Oncogene</i> , 2000, pp. 2557-2565, Vol. 19.	
	R28	LIN, T. S. <i>et al.</i> "STAT signaling in the pathogenesis and treatment of leukemias" <i>Oncogene</i> , 2000, pp. 2496-2504, Vol. 19.	
	R29	LIN, J. <i>et al.</i> "The role of Stat5a and Stat5b in signaling by IL-2 family cytokines" <i>Oncogene</i> , 2000, pp. 2566-2576, Vol. 19.	
	R30	MERRIFIELD R. B. "Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide" <i>Am. Chem. Soc.</i> , July 20, 1963, pp. 2149-2152, Vol. 85.	
	R31	ROJAS, M. <i>et al.</i> "Genetic engineering of proteins with cell membrane permeability" <i>Nature Biotechnology</i> , April 1998, pp. 370-375, Vol. 16.	
	R32	SASSE, J. <i>et al.</i> "Mutational Analysis of Acute-Phase Response Factor/Stat3 Activation and Dimerization" <i>Molecular and Cellular Biology</i> , August 1997, pp. 4677-4686, Vol. 17, No. 8.	
	R33	SCHINDLER, C. <i>et al.</i> "Transcriptional Responses to Polypeptide Ligands: The JAK-STAT Pathway" <i>Annu. Rev. Biochem.</i> , 1995, pp. 621-651, Vol. 64.	
	R34	SEIDEL, H. M. <i>et al.</i> "Spacing of palindromic half sites as a determinant of selective STAT (signal transducers and activators of transcription) DNA binding and transcriptional activity" <i>Proc. Natl. Acad. Sci. USA</i> , March 2, 1995, pp. 3041-3045, Vol. 92.	
	R35	SEIDEL, H. M. <i>et al.</i> "Pharmaceutical intervention in the JAK/STAT signaling pathway" <i>Oncogene</i> , 2000, pp. 2645-2656, Vol. 19.	
	R36	SHUAI, K. <i>et al.</i> "A Single Phosphotyrosine Residue of Stat91 Required for Gene Activation by Interferon- γ " <i>Science</i> , September 24, 1993, pp. 1744-1746, Vol. 261.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/784,309
				Filing Date	February 20, 2004
				First Named Inventor	James Turkson
				Group Art Unit	1614
				Examiner Name	
Sheet	5	of	6	Attorney Docket Number	USF-T194XC1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R37	SHUAI, K. <i>et al.</i> "Interferon Activation of the Transcription Factor Stat91 Involves Dimerization through SH2-Phosphotyrosyl Peptide Interactions" <i>Cell</i> , March 11, 1994, pp. 821-828, Vol. 76.	
	R38	SMITHGALL, T. E. <i>et al.</i> "Control of myeloid differentiation and survival by Stats" <i>Oncogene</i> , 2000, pp. 2612-2618, Vol. 19.	
	R39	SONG, J. I. <i>et al.</i> "STAT signaling in head and neck cancer" <i>Oncogene</i> , 2000, pp. 2489-2495, Vol. 19.	
	R40	SONG, L. <i>et al.</i> "Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells" <i>Oncogene</i> , 2003, pp. 4150-4165, Vol. 22.	
	R41	STARK, G. R. <i>et al.</i> "How Cells Respond to Interferons" <i>Annu. Rev. Biochem.</i> , 1998, pp. 227-264, Vol. 67.	
	R42	TURKSON, J. <i>et al.</i> "Stat3 Activation by Src Induces Specific Gene Regulation and Is Required for Cell Transformation" <i>Molecular and Cellular Biology</i> , May 1998, pp. 2545-2552, Vol. 18, No. 5.	
	R43	TURKSON, J. <i>et al.</i> "Requirement for Ras/Rac1-Mediated p38 and c-Jun N-Terminal Kinase Signaling in Stat3 Transcriptional Activity Induced by the Src Oncoprotein" <i>Molecular and Cellular Biology</i> , November 1999, pp. 7519-7528, Vol. 19, No. 11.	
	R44	TURKSON, J. <i>et al.</i> "STAT proteins: novel molecular targets for cancer drug discovery" <i>Oncogene</i> , 2000, pp. 6613-6626, Vol. 19.	
	R45	TURKSON, J. <i>et al.</i> "Phosphotyrosyl Peptides Block Stat3-mediated DNA Binding Activity, Gene Regulation, and Cell Transformation" <i>The Journal of Biological Chemistry</i> , November 30, 2001, pp. 45443-45455, Vol. 276, No. 48.	
	R46	WAGNER, B. <i>et al.</i> "The SIF binding element confers sis/PDGF inducibility onto the c-fos promoter" <i>The EMBO Journal</i> , 1990, pp. 4477-4484, Vol. 9, No. 13.	
	R47	YAMAUCHI, K. <i>et al.</i> "Phosphatidylinositol 3-Kinase Functions Upstream of Ras and Raf in Mediating Insulin Stimulation of c-fos Transcription" <i>The Journal of Biological Chemistry</i> , July 15, 1993, pp. 14597-14600, Vol. 268, No. 20.	
	R48	YU, C. <i>et al.</i> "Enhanced DNA-Binding Activity of a Stat3-Related Protein in Cells Transformed by the Src Oncoprotein" <i>Science</i> , July 7, 1995, pp. 81-83, Vol. 269.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/784,309		
		Filing Date	February 20, 2004		
		First Named Inventor	James Turkson		
		Group Art Unit	1614		
		Examiner Name			
Sheet	6	of	6	Attorney Docket Number	USF-T194XC1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R49	ZHANG, Y. <i>et al.</i> "Activation of Stat3 in v-Src-transformed Fibroblasts Requires Cooperation of Jak1 Kinase Activity" <i>The Journal of Biological Chemistry</i> , August 11, 2000, pp. 24935-24944, Vol. 275, No. 32.	
	R50	POSTERNAK, T. <i>et al.</i> "De la protection contre l'hydrolyse enzymatique exercée par les groupes phosphoryles II." <i>Helv. Chim. Acta.</i> , 1945, pp. 1258-1270, Vol. 28.	
	R51		
	R52		
	R53		
	R54		
	R55		
	R56		
	R57		
	R58		
	R59		
	R60		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.